James Kihara, who serves as the Principal Accounting Officer for Acadia Pharmaceuticals Inc (NASDAQ: ACAD), has engaged in a transaction involving the sale of company common stock. On May 4, 2026, Kihara disposed of 1,332 shares, a move that generated $29,024 in total proceeds. The shares were sold within a price range between $21.79 and $21.815 per share.
The sale was not a discretionary market transaction but rather a mandatory sale designed to cover withholding taxes and other tax-related obligations stemming from the vesting of restricted stock units (RSUs). This specific execution was conducted under the framework of a Rule 10b5-1 trading plan. To provide context for this disposal, Kihara had previously acquired 2,596 shares of common stock on May 1, 2026, as a result of RSU vesting. These restricted stock units represent a contingent right to receive one share of the company's common stock, with the specific units in question scheduled to vest in four equal annual installments starting from May 1, 2024.
Following these series of transactions, Kihara maintains a direct holding of 29,129 shares of Acadia Pharmaceuticals Inc common stock. At the time of reporting, the stock is trading at $22.34, which sits slightly above the price range established during Kihara's recent sale.
Market Context and Valuation
The company is approaching a significant milestone with earnings scheduled to be reported tomorrow, May 6. From a valuation perspective, InvestingPro analysis suggests that ACAD may be undervalued, noting that it is trading at a low P/E ratio relative to its near-term earnings growth potential, supported by a PEG ratio of 0.14.
Regulatory and Analyst Developments
Recent news for the pharmaceutical company includes a setback in Europe. The Committee for Medicinal Products for Human Use within the European Medicines Agency adopted a negative opinion concerning Acadia's Marketing Authorization Application for trofinetide, intended for the treatment of Rett syndrome. The committee highlighted specific concerns regarding the limited observed treatment effect after a 12-week period and noted that the study failed to capture all core symptoms associated with Rett syndrome.
In response to these regulatory hurdles, BofA Securities adjusted its outlook. The firm lowered its price target for Acadia Pharmaceuticals from $31 to $29 while maintaining a Neutral rating. However, BofA Securities also provided an upgrade, moving the company from Neutral to Buy, based on the assessment that recent declines in share price were driven by macroeconomic factors rather than the fundamental health of the company.
Additionally, Acadia has undergone leadership changes at the board level, appointing Jonathan M. Poole to its board of directors and audit committee. Mr. Poole will serve as a Class II director, with his current term set to expire at the 2027 annual meeting of stockholders.